A Study of Soticlestat in Adults and Children With Rare Epilepsies

Summary

The main aim is to assess the long-term safety and tolerability of soticlestat when used along with other anti-seizure treatment. Participants will receive soticlestat twice a day. Participants will visit the study clinic every 2-6 months throughout the study. Study treatments may continue as long as the participant is receiving benefit from it.

Timeline

Start

2018-07-19

Primary completion

2025-07-30

Completion

2025-07-30

Outcome

Outcome not reported

Stopped: “Due to negative results from phase 3 SKYLINE and SKYWAY studies and unrelated to patient safety it has been determined that supplementary data from TAK-935-18-001 study is no longer necessary. Therefore, Takeda has made a decision to close this study”

Drugs

Indications